Differential expression of Tim3 protein in colorectal cancer associated with MSI and Brafmutation
- 1 May 2022
- journal article
- research article
- Vol. 37 (5) , 441-448
Abstract
Tim3 is a negative immune checkpoint molecule and plays a crucial part in tumor-induced immune suppression. Tim3 is a cell surface molecule expressed on T cells marking dysfunctional CD8+ cells in various kinds of cancers. Tim3 expression was mainly reported in tumor-infiltrating lymphocytes (TILs). There are few studies focusing on the expression of Tim3 in tumor cells. Immunohistochemistry was performed to determine Tim3 expression level. The relationships between Tim3 expression in colorectal cancer cells and in tumor-infiltrating lymphocytes and cilicopathological parameters were statistically analyzed. Tim3 was differentially detected in TILs and in colorectal cancer cells. Positive expression of Tim3 in colorectal cancer cells was associated with tumor location (P=0.001), depth of tumor invasion (P<0.001), lymph node metastasis (P=0.001), TNM stage (P=0.001), MSI (P=0.008), and Braf V600E mutation (P=0.001). On the other hand, positive expression of Tim3 in TILs was only related to depth of tumor invasion (P<0.001). Positive expression of Tim3 in both colorectal cancer cells and TILs was associated with depth of tumor invasion (P<0.001), lymph node metastasis (P=0.002), TNM stage (P=0.002), MSI (P=0.039), and Braf V600E mutation (P=0.009). Kaplan-Meier survival analysis showed that Tim3 expression in colorectal cancer and in TILs was significantly associated with patient overall survival (OS) rate (P=0.039, and 0.001). Tim3 may be a potential prognostic marker and a therapy target for colorectal cancer.Keywords
This publication has 33 references indexed in Scilit:
- Down-regulated expression of Tim-3 promotes invasion and metastasis of colorectal cancer cellsNeoplasma, 2017
- Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometryCancer Immunology, Immunotherapy, 2016
- PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutationsCancer Biology & Therapy, 2016
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patientsBritish Journal of Cancer, 2014
- Prospects for TIM3-Targeted Antitumor ImmunotherapyCancer Research, 2011
- Microsatellite instability in the management of colorectal cancerExpert Review of Gastroenterology & Hepatology, 2011
- Microsatellite Instability, Prognosis and Drug Sensitivity of Stage II and III Colorectal Cancer: More Complexity to the PuzzleJNCI: Journal of the National Cancer Institute, 2011
- Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established TumorsCancer Research, 2011
- Tim3 binding to galectin-9 stimulates antimicrobial immunityJournal of Experimental Medicine, 2010
- Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune diseaseNature, 2002